Trial Profile
Phase II multicentric study to evaluate the efficacy and the safety of Bendamustine in adjunct to Etoposide, Aracytabin and Melphalan (BeEAM) as a preparative regimen for autologous stem cell transplantation in refractory/relapsed aggressive B-cell non-Hodgkin lymphoma patients [Studio di fase II, multicentrico, per valutare la sicurezza e l'efficacia di Bendamustina in aggiunta a Etoposide, Citosina Arabinoside e Melphalan come regime di condizionamento al trapianto autologo in pazienti affetti da linfoma non-Hodgkin B aggressivo ricaduti/resistenti]
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Aug 2021
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Cytarabine; Etoposide; Melphalan
- Indications Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 29 Aug 2021 Status changed from recruiting to completed.
- 19 Oct 2012 Planned end date added (8 Jun 2016) as reported by European Clinical Trials Database record.
- 02 Apr 2012 New trial record